Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will hold its 3Q20 earnings conference call with the financial community on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.ironwoodpharma.com
Earnings Expectation
Ironwood Pharmaceuticals, Inc. is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.15 per share from revenue of $ 95.96 million. Looking ahead, the full year income are expected at $ 0.55 per share on the revenues of $ 369.15 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 360.00 million ~ $ 380.00 million
Click Here For More Historical Outlooks Of Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung.
